Prostate Specific Antigen (PSA) Testing Market

Market Synopsis:

The global Prostate Specific Antigen (PSA) Testing Market is valued at USD 4.1 Billion in 2024 and is projected to reach a value of USD 13.36 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 11.35% between 2025 and 2035. During the forecast period, technological developments in diagnostic tests are expected to boost market expansion even further. Researchers are currently studying the use of Artificial Intelligence (AI) to identify prostate cancer, according to the National Cancer Institute. Artificial intelligence (AI) algorithms are utilized to identify worrisome spots seen during an MRI scan that require biopsies to confirm the presence of cancer cells. Artificial intelligence methods are also being tested in order to improve biopsy sample analysis so that more efficient and accurate results may be provided.

Another factor that is expected to fuel the expansion of the prostate cancer diagnostics market in the near future is the increasing number of new market entrants. In comparison to standard PSA testing, this device is predicted to provide very sensitive test findings. As a result, increased investment by new entrants is likely to considerably fuel growth. The exorbitant expense of the tests, on the other hand, is expected to stifle growth.

Increased Level of Awareness

Owing to the growing senior population, the market for prostate specific antigen testing is booming. Increased public awareness about the benefits of prostate cancer screening, technological advancements in testing and treating prostate cancer, and a variety of reimbursement policies for prostate cancer treatments in various developed and developing regions are all influencing the growth of the prostate specific antigen market. According to the 2017 National Population Projections from the United States Census Bureau. By 2030, all baby boomers will be over 65, implying that one out of every five residents will be retired. This reflects the increasing number of the geriatric population.

False-positive or False-negative results of PSA

Owing to false-positive or false-negative PSA test findings, the prostate specific antigen testing market is facing certain difficulties. In addition, most of these tests, such as PSA Screening, have several adverse effects, such as difficulty passing urine, effects on bowel function, erectile dysfunction, and frequent aches, which hampered the expansion of the Prostate Specific Antigen Testing market. Higher technological advancements that result in more streamlined and accurate results in tests like the Prostate Health Index (phi) may slow the growth of the PSA testing industry unless the way the tests are handled changes.

Market Segmentation:

The Global Prostate Specific Antigen (PSA) Testing Market can be segmented by Product Type into Preliminary Tests and Confirmatory Tests (PCA3 Tests, Trans-rectal Ultrasound and Biopsy). Based on Region, the Prostate Specific Antigen (PSA) Testing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Due to an increase in the frequency of prostate cancer, the preliminary test category is likely to hold the biggest market share over the projection period. The American Institute for Cancer Research claims that the widespread availability of PSA screening has aided early detection and treatment, resulting in higher survival rates. PSA testing discover previously undetected and tiny lesions that may or may not progress to a more advanced stage of cancer. Most men over the age of 50, as well as those at risk of acquiring the disease, should get these tests since they help diagnose the disease before serious symptoms arise.

North America to Continue Dominating the Prostate Specific Antigen (PSA) Testing Market

Owing to the high prevalence of the condition and the rise in government programs to aid early diagnosis, North America held the biggest market share in 2021. The National Cancer Institute, for example, has developed various projects to improve early detection and treatment research. Cancer Biomarkers Research Group is one of their programs that promotes biomarker research. Similarly, the organisation oversees the Early Detection Research Network (EDRN), a collaborative network of privately financed and government-supported researchers dedicated to the identification and validation of cancer biomarkers.

{{Map_Revenue}}

Key Players:

Some of the major market players areMDx Health (US), Myriad Genetics Inc (US)., Abbott Laboratories (US), F. Hoffman-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), OPKO Health Inc. (US), and Genomic Health (US).

The Prostate Specific Antigen (PSA) Testing market is segmented as follows:

By {{segment_1}} (Revenue: USD Billion, 2016 - 2028)

• {{segment_1_1}}
• {{segment_1_2}}

By Region (Revenue: USD Billion, 2016 - 2028)

• North America

o U.S.

o Canada

o Mexico

• Europe

o U.K.

o France

o Germany

o Italy

o Spain

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o South East Asia

o Rest of Asia Pacific

• Latin America

o Brazil

o Argentina

o Rest of Latin America

• Middle East & Africa

o GCC Countries

o South Africa

o Rest of Middle East & Africa